Skip to content

Join The Lazy Contractor's Blueprint live on Nov 28 — show up and get 1,000 free Mindy creditsJoin The Lazy Contractor's Blueprint, free and live on Nov 28

Register free
Home/Contractors/Locus Biosciences INC/contracts

Federal Contractor Profile

Locus Biosciences INC

$82M obligated·2 awards·1 agencies·1 NAICS
OverviewContractsAgenciesNAICS

Federal Contracts

Showing award actions 1–9 of 9 funded award actions, most recent first.

Contracts with positive obligations
2
Funded award actions shown
9
Obligations shown
$82M
Awarding agencies
1

This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.

Award data as of October 16, 2026. Source: USAspending federal award records.

DateAgencyPIIDNAICSDescriptionAmount
Oct 16, 2026Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93025C00035541714ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY$5.3M
May 11, 2026Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93025C00035541714ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY$4.6M
Sep 22, 2025Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93025C00035541714ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY$3.3M
Sep 16, 2025Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50120C00169541714CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS$18M
Feb 21, 2025Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50120C00169541714CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS$6.9M
Jan 19, 2024Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50120C00169541714CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS$24M
Feb 15, 2023Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50120C00169541714CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS$7.8M
Jun 22, 2022Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50120C00169541714CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS$6.2M
Sep 28, 2020Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50120C00169541714CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS$11M

Get Alerted Before Locus Biosciences INC's Next Recompete

Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.

Start for free